J33

6,7-bis(chloranyl)-3,5-dihydro-1H-imidazo[2,1-b]quinazolin-2-one

Created:2021-03-26
Last modified:  2021-09-29

Help

Find related ligands:

Chemical Details

Formal Charge0
Atom Count23
Chiral Atom Count0
Bond Count25
Aromatic Bond Count6
2D diagram of J33
Toggle HydrogenToggle Labels

Chemical Component Summary

Name6,7-bis(chloranyl)-3,5-dihydro-1H-imidazo[2,1-b]quinazolin-2-one
Systematic Name (OpenEye OEToolkits)6,7-bis(chloranyl)-3,5-dihydro-1~{H}-imidazo[2,1-b]quinazolin-2-one
FormulaC10 H7 Cl2 N3 O
Molecular Weight256.088
TypeNON-POLYMER

Chemical Descriptors

TypeProgramVersionDescriptor
SMILESCACTVS3.385Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl
SMILESOpenEye OEToolkits2.0.7c1cc(c(c2c1N=C3NC(=O)CN3C2)Cl)Cl
Canonical SMILESCACTVS3.385 Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl
Canonical SMILESOpenEye OEToolkits2.0.7 c1cc(c(c2c1N=C3NC(=O)CN3C2)Cl)Cl
InChIInChI1.03 InChI=1S/C10H7Cl2N3O/c11-6-1-2-7-5(9(6)12)3-15-4-8(16)14-10(15)13-7/h1-2H,3-4H2,(H,13,14,16)
InChIKeyInChI1.03 OTBXOEAOVRKTNQ-UHFFFAOYSA-N

Drug Info: DrugBank

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
DrugBank IDDB00261 
NameAnagrelide
Groups approved
DescriptionAnagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms.[L14153] It is an oral imidazoquinazoline that was first approved for use in the US in 1997.[A214274] It appears to carry a better response rate than other thrombocythemia treatments (e.g. [busulfan], [hydroxyurea]) and may be better tolerated.[A214274]
Synonyms
  • Anagrelide hydrochloride
  • Anagrelide hydrochloride monohydrate
  • Anagrelidum
  • Anagrelida
  • Anagrelide
Brand Names
  • PHL-anagrelide
  • PMS-anagrelide
  • Agrylin
  • Dom-anagrelide
  • Sandoz Anagrelide
IndicationAnagrelide is indicated for the treatment of thrombocythemia, secondary to malignant neoplasms, to reduce platelet count and the associated risk of thrombosis. It is also beneficial in the amelioration of thrombocythemia symptoms including thrombo-hemorrhagic events.[L14153]
Categories
  • Agents producing tachycardia
  • Antineoplastic Agents
  • Antineoplastic and Immunomodulating Agents
  • Antiplatelet agents
  • Cardiovascular Agents
ATC-CodeL01XX35
CAS number68475-42-3

Drug Targets

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
NameTarget SequencePharmacological ActionActions
cGMP-inhibited 3',5'-cyclic phosphodiesterase 3AMAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDL...unknowninhibitor
Cytochrome P450 1A2MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPL...unknownsubstrate,inhibitor
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
Pharos CHEMBL760
PubChem 2182, 135409400
ChEMBL CHEMBL760
ChEBI CHEBI:142290